Biomerica, Inc.
BMRA
$3.88
$0.123.19%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.03% | 4.40% | 5.49% | 0.72% | -8.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.03% | 4.40% | 5.49% | 0.72% | -8.46% |
| Cost of Revenue | -5.66% | -3.46% | 16.68% | 1.58% | 17.66% |
| Gross Profit | 112.75% | 34.46% | -29.85% | -31.03% | -224.17% |
| SG&A Expenses | -32.89% | -22.88% | 16.04% | -14.24% | 9.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.80% | -17.20% | 7.81% | -10.19% | 9.23% |
| Operating Income | 39.50% | 38.25% | -11.04% | 16.78% | -21.14% |
| Income Before Tax | 39.03% | 36.42% | -18.30% | 20.52% | -18.51% |
| Income Tax Expenses | -200.00% | -137.50% | -82.61% | -46.15% | -88.57% |
| Earnings from Continuing Operations | 39.36% | 36.96% | -16.25% | 20.70% | -16.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.36% | 36.96% | -16.25% | 20.70% | -16.24% |
| EBIT | 39.50% | 38.25% | -11.04% | 16.78% | -21.14% |
| EBITDA | 39.95% | 38.93% | -11.23% | 17.16% | -21.25% |
| EPS Basic | 46.84% | 38.06% | -16.20% | 21.76% | 6.86% |
| Normalized Basic EPS | 46.55% | 37.52% | -18.20% | 21.64% | 5.07% |
| EPS Diluted | 46.84% | 33.33% | -14.29% | 16.67% | 6.86% |
| Normalized Diluted EPS | 46.55% | 37.52% | -18.20% | 21.64% | 5.07% |
| Average Basic Shares Outstanding | 14.06% | 1.78% | 0.00% | 1.37% | 24.78% |
| Average Diluted Shares Outstanding | 14.06% | 1.78% | 0.00% | 1.37% | 24.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |